Q1 EPS Estimate for Nurix Therapeutics Increased by Analyst

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Analysts at HC Wainwright upped their Q1 2025 earnings estimates for Nurix Therapeutics in a report released on Wednesday, April 2nd. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.60) per share for the quarter, up from their previous forecast of ($0.72). HC Wainwright currently has a "Buy" rating and a $36.00 price target on the stock. The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Nurix Therapeutics' FY2025 earnings at ($2.88) EPS.

Other research analysts have also issued reports about the stock. Stifel Nicolaus decreased their price target on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday. Leerink Partnrs upgraded shares of Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. Morgan Stanley upped their price target on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a research note on Monday, February 3rd. Wells Fargo & Company lowered their price objective on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday. Finally, Stephens reissued an "overweight" rating and issued a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $30.44.

Nurix Therapeutics Trading Up 3.7 %

NRIX traded up $0.33 during trading on Monday, reaching $9.14. The stock had a trading volume of 900,297 shares, compared to its average volume of 909,562. The company has a market capitalization of $696.80 million, a price-to-earnings ratio of -3.16 and a beta of 2.23. The stock's 50 day moving average is $14.03 and its two-hundred day moving average is $19.18. Nurix Therapeutics has a one year low of $8.18 and a one year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The firm had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. During the same quarter in the prior year, the company earned ($0.76) EPS.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its stake in shares of Nurix Therapeutics by 85.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock worth $1,531,000 after purchasing an additional 31,352 shares in the last quarter. Barclays PLC increased its position in Nurix Therapeutics by 77.9% in the third quarter. Barclays PLC now owns 128,344 shares of the company's stock worth $2,884,000 after buying an additional 56,190 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Nurix Therapeutics by 42.7% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after buying an additional 235,971 shares during the period. FMR LLC lifted its position in shares of Nurix Therapeutics by 675.9% during the 3rd quarter. FMR LLC now owns 586,902 shares of the company's stock valued at $13,188,000 after buying an additional 511,256 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Nurix Therapeutics during the 4th quarter valued at approximately $1,026,000.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,811 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the transaction, the chief financial officer now owns 39,549 shares of the company's stock, valued at approximately $785,047.65. This represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the firm's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the transaction, the insider now directly owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock worth $213,449 over the last quarter. Company insiders own 9.80% of the company's stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.